A Prospective, Single-arm, Multicenter Study to Explore the Efficacy and Safety of Vunakizumab in Adults with Active Spondyloarthritis
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Vunakizumab (Primary)
- Indications Spondylarthritis
- Focus Therapeutic Use
- Acronyms V SPA
- 20 Jan 2025 New trial record